Literature DB >> 1839447

Pharmacokinetics of clodronate after single intravenous, intramuscular and subcutaneous injections in rats.

L Laurén1, T Osterman, T Karhi.   

Abstract

The pharmacokinetics of clodronate was studied in rats after single intravenous, intramuscular and subcutaneous doses of a mixture of unlabelled and 14C-labelled disodium clodronate (25 mg/5 muCi/kg). The peak clodronate concentration in plasma was reached within 5 min., and the drug was eliminated with a half-life of about 1.5 hr regardless of administration route. Bioavailabilities after intramuscular and subcutaneous administration were 105% and 89%, respectively. During the 72 hr collection period, the mean share of clodronate recovered from the urine was about 53% of the dose regardless of administration route. Most of the drug was excreted during the first 24 hr. The amount of clodronate in bone (femur) was 186 micrograms/g tissue at 2 hr after intravenous administration, 188 micrograms/g after intramuscular administration and 157 micrograms/g after subcutaneous administration. It is concluded that absorption of clodronate after intramuscular and subcutaneous administration is rapid and good, and that the concentrations of the drug in bone after 2 hr are about the same as after intravenous administration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1839447     DOI: 10.1111/j.1600-0773.1991.tb01312.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  5 in total

Review 1.  Clodronate: a review of its use in breast cancer.

Authors:  M Hurst; S Noble
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

2.  Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells.

Authors:  S D Hafeman; D Varland; S W Dow
Journal:  Vet Comp Oncol       Date:  2011-05-18       Impact factor: 2.613

3.  Long-term release of clodronate from biodegradable microspheres.

Authors:  P Perugini; I Genta; B Conti; T Modena; F Pavanetto
Journal:  AAPS PharmSciTech       Date:  2001-07-11       Impact factor: 3.246

Review 4.  Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.

Authors:  Frieder Bauss; R Graham G Russell
Journal:  Osteoporos Int       Date:  2004-03-26       Impact factor: 4.507

5.  Local delivery of hydrogel encapsulated vascular endothelial growth factor for the prevention of medication-related osteonecrosis of the jaw.

Authors:  Dileep Sharma; Stephen Hamlet; Cedryck Vaquette; Eugen Bogdan Petcu; Poornima Ramamurthy; Saso Ivanovski
Journal:  Sci Rep       Date:  2021-12-03       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.